{
    "clinical_study": {
        "@rank": "8264", 
        "brief_summary": {
            "textblock": "This registry is intended to evaluate the impact of genomic test results towards selecting a\n      first-line therapy option for newly diagnosed localized prostate cancer patients."
        }, 
        "brief_title": "Open Registry Measuring Impact of Genomic Testing on Treatment of Prostate Cancer Patients", 
        "condition": "Prostate Cancer", 
        "condition_browse": {
            "mesh_term": "Prostatic Neoplasms"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Newly diagnosed (\u22646 months), untreated patients with histologically proven\n             adenocarcinoma of the prostate that have the following characteristics.\n\n          -  Clinically localized (no evidence on clinical or imaging studies of advanced\n             disease).\n\n          -  No hormonal therapy including LHRH (luteinizing hormone-releasing hormone) agonist or\n             antagonist, anti-androgen, estrogens or exogenous androgens, when applicable.\n\n          -  Sufficient amount of tissue remains from biopsy to perform genomic testing.\n\n        Exclusion Criteria:\n\n          -  Patients with a known history of hypogonadism"
            }, 
            "gender": "Male", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years", 
            "sampling_method": "Non-Probability Sample", 
            "study_pop": {
                "textblock": "Recently diagnosed treatment-na\u00efve patients with early stage localized prostate cancer"
            }
        }, 
        "enrollment": {
            "#text": "1100", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "September 26, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01954004", 
            "org_study_id": "PROCEDE-1000"
        }, 
        "is_fda_regulated": "No", 
        "lastchanged_date": "September 26, 2013", 
        "location": {
            "facility": {
                "address": {
                    "city": "Salt Lake City", 
                    "country": "United States", 
                    "state": "Utah"
                }
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_groups": "1", 
        "official_title": "An Open Registry to Measure the Impact of Adding Genomic Testing (Prolaris\u00ae) on the Treatment Decision Following Biopsy in Newly Diagnosed Prostate Cancer Patients", 
        "other_outcome": {
            "measure": "\u2022 The mean change in the physician's likelihood of recommending non-interventional therapy (watchful waiting or active surveillance) post-genomic testing compared to pre-genomic testing.", 
            "safety_issue": "No", 
            "time_frame": "4 months"
        }, 
        "overall_contact": {
            "email": "krushton@myriad.com", 
            "last_name": "Kristen Rushton"
        }, 
        "overall_official": {
            "affiliation": "Myriad Genetic Laboratories, Inc.", 
            "last_name": "Abebe Haregewoin, MD, PhD", 
            "role": "Study Director"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "United States: Institutional Review Board", 
            "has_dmc": "No"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "April 2015", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "Percentage change from the recorded PRE-Prolaris\u00ae test treatment option versus the ACTUAL treatment option implemented following results of genomic risk assessment testing (Prolaris\u00ae).", 
            "safety_issue": "No", 
            "time_frame": "4 months"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01954004"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "Percentage change from the recorded PRE-Prolaris\u00ae test treatment option versus the POST-Prolaris\u00ae test treatment plan following review of the genomic test results (prior to patient consultation)", 
                "safety_issue": "No", 
                "time_frame": "1 month"
            }, 
            {
                "measure": "Percentage change from the recorded PRE-Prolaris\u00ae test treatment option versus the POST-Prolaris\u00ae test treatment plan following consultation with the patient.", 
                "safety_issue": "No", 
                "time_frame": "2 months"
            }
        ], 
        "source": "Myriad Genetic Laboratories, Inc.", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Myriad Genetic Laboratories, Inc.", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "April 2013", 
        "study_design": "Observational Model: Cohort, Time Perspective: Prospective", 
        "study_type": "Observational [Patient Registry]", 
        "target_duration": "4 Months", 
        "verification_date": "September 2013"
    }
}